Dr Matt Seymour discusses how the National Cancer Research Network is acting to build collaborations between UK clinical studies groups and pharmaceutical companies to allow patients to access new therapeutic agents at an earlier stage. Dr Seymour explains how the Experimental Cancer Medicine Network is facilitating the simultaneous operation of phase II studies with clinical trials assessing potential combination therapies, outlines the problems that have emerged and the steps that have been taken to overcome these.